Learn what Wall Street already knows in our "Billion Dollar Secret" guide.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Boston Scientific Unveils PREDICt-RM Data
BSX ICUI ENZY
Boston Scientific Corporation ( BSX - Analyst Report) announced results from the PREDICt-RM (Patient RElated Determinants of ICD Remote Monitoring Utilization and Outcomes) study which revealed that patients using the wireless telemetry-infused LATITUDE Remote Patient Management system of the company demonstrated significantly reduced mortality and fewer hospitalizations compared to those using LATITUDE-compatible devices but not followed on the system. The results were presented at the Heart Rhythm Society's 35th Annual Scientific Sessions in San Francisco.
Following the news, Boston Scientific's share price increased 1.6% to close at $12.93 on May 12.
The PREDICt-RM study also demonstrated a relative reduction of 33% in mortality risk in patients administered with Boston Scientific's ICDs and CRT-Ds, who were remotely monitored via the LATITUDE wireless remote monitoring system, compared to ICD and CRT-D patients who were not remotely monitored. Further, these patients also experienced a 19% relative reduction in hospitalizations for any cause.
The study outcomes presented at the session were a result of a research collaboration conducted between Yale CORE, the American College of Cardiology (ACC), and Boston Scientific.
Management hopes this study will throw light on clinical practice guidelines and promote the routine use of LATITUDE system with wireless remote monitoring technology in daily practice. However, this technology is still underutilized among ICD and CRT-D patients, though it has widespread availability and patients using it have benefited through advanced outcomes, as has been demonstrated in the PREDICt-RM study.
The PREDICt-RM study combined the National Cardiovascular Data Registry (NCDR) from ACC, CMS data from Medicare, and the Boston Scientific LATITUDE system, because no single database could have provided the entire data effectively. The results from this study were made possible through a unique research design that linked these three large health care databases, in turn reflecting the scope that lies for big data and healthcare analytics to improve patient care.
The LATITUDE Remote Patient Management system connects a home communicator to the patient's implanted Boston Scientific device through wireless telemetry, enabling automatic collection of patient data. The system can transmit physiologic data, as well as data gathered from the implanted device to the healthcare team's LATITUDE website.
PREDICt-RM has successfully proven that wireless remote monitoring using the LATITUDE system can emerge as a boon for patients, benefiting the overall healthcare system. Scientists at Yale CORE feel that the innovative collaboration with ACC and Boston Scientific has enabled them to leverage the strengths of each database in developing a deeper understanding of the association of remote monitoring with patient outcomes.
Boston Scientific currently holds a Zacks Rank #3 (Hold). Some better-ranked stocks worth considering in the medical products industry include Enzymotec Ltd. ( ENZY - Snapshot Report) , Cardica Inc. and ICU Medical, Inc. ( ICUI - Snapshot Report) . All these stocks carry a Zacks Rank #2 (Buy).